Is Edwards Lifesciences (EW) Priced Fairly After Recent Share Price Swings?

• If you are wondering whether Edwards Lifesciences is attractively priced or not, the key is to separate the share price story from the underlying value story.
• The stock last closed at US$81.05, with returns of 2.2% over 7 days, a 3.4% decline over 30 days, a 5.0% decline year to date, but a 16.9% gain over the past year that may catch your eye.
• Recent coverage has focused on how Edwards Lifesciences fits into longer term themes in medical devices and investor sentiment toward the broader healthcare sector, which helps frame these mixed return numbers. For valuation, that context matters because it shapes how the market currently prices growth potential and risk.
• On Simply Wall St's valuation model the company records a value score of 1 out of 6. Next up is a closer look at what different valuation methods say about Edwards Lifesciences, and why the more complete way of thinking about value at the end of this article could change how you view that score.

Edwards Lifesciences scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Edwards Lifesciences Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of the cash a business could generate in the future and discounts those cash flows back to today, using a required rate of return, to arrive at an estimate of what the whole company might be worth now.

For Edwards Lifesciences, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $1.29b, and analysts plus extrapolated estimates point to free cash flow of $2.06b by 2028. Simply Wall St extends those projections out a full decade, with annual figures between roughly $1.55b and $3.17b, all brought back to today’s dollars using discount factors.

On this basis, the DCF model produces an estimated intrinsic value of about $88.88 per share. Compared with the recent share price of US$81.05, this suggests an intrinsic discount of around 8.8%, which is relatively small and within a reasonable margin of estimation error.

Result: ABOUT RIGHT

Edwards Lifesciences is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Edwards Lifesciences.

Approach 2: Edwards Lifesciences Price vs Earnings

For profitable companies, the P/E ratio is a straightforward way to relate what you pay for each share to the earnings that support that price. It helps you see how many dollars investors are currently willing to pay for each dollar of earnings.

What counts as a “normal” P/E will usually reflect how the market views a company’s growth prospects and risk. Higher growth expectations and lower perceived risk tend to justify a higher multiple, while slower growth or higher risk usually point to a lower one.

Edwards Lifesciences currently trades on a P/E of 44.08x. That sits above the Medical Equipment industry average of 26.58x and also above the peer group average of 26.28x, so on simple comparisons the shares look more expensive than many peers.

Simply Wall St’s Fair Ratio for Edwards Lifesciences is 32.82x. This is an estimate of what its P/E might be given factors such as earnings growth, industry, profit margin, market cap and risk profile. This Fair Ratio is more tailored than a plain peer or industry comparison because it adjusts for the company’s own characteristics instead of assuming all Medical Equipment stocks deserve the same multiple.

Comparing the current P/E of 44.08x with the Fair Ratio of 32.82x suggests the shares trade above this modelled range.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Edwards Lifesciences Narrative

Earlier it was mentioned that there is an even better way to think about valuation. On Simply Wall St that means using Narratives, where you set out your story for Edwards Lifesciences, link that story to specific forecasts for revenue, earnings and margins, and let the platform turn that into a fair value that you can compare with the current price. You can see this alongside other community views on the company within the Community page, watch it update automatically when fresh news or earnings land, and compare very different perspectives such as a more optimistic view that supports a fair value closer to US$110 and a cautious view closer to US$84. This way you can decide which story you believe and whether the current market price lines up with it.

Do you think there's more to the story for Edwards Lifesciences? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com